The Delhi-based Panacea Biotec is planning to strengthen its presence in diabetology segment in the domestic market. The recent introduction of Pangraph 0.5, 1 & 5 Tablets (Anti-diabetic) and the acceptance of Glizid M (anti-diabetic), which achieved record sales during 2003-'04 and stands at No. 1 position in the Gliclazide + Metformin segment are proof of its strong presence in the specialty, claims the company.

According to Panacea spokesperson, the company has launched anti-tuberculosis, anti-diabetics and diabetic neuropathy drugs in the domestic market recently. During June'04 quarter, the company introduced Xeed 4, Xeed 3E & Xeed 2 Tablets (Anti-tuberculosis), and Myelogen Tablets (for Diabetic Neuropathy) in addition to Pangraph 0.5, 1 & 5, he stated.

The company has strong presence in specialties like Diabetology, Cardiology, Nephrology, Orthopaedics, Dentistry, ENT, Surgery and Paediatrics etc. Its brands are being well accepted by the medical fraternity and enjoy excellent market share in their therapeutic segments, he said.

Panacea's Nimulid Transgel continues to enjoy the top ranking in Nimesulide topical gel segment and Nimulid (pain management), Nimulid DS, Alphadol, Alphadol C, Livoluk, Myser, Glizid, Pioryl are the brands challenging the leader at 2nd position in their respective categories.

The Company has launched number of new brands during 2003-'04 including Betaglim M (combination of Glimepiride and Metformin) positioned in cardia-diabetic segment, Metlong 1000 (a brand extension for treatment of type 2 Diabetes), Glizid MR 60 (a brand extension of Glizid MR for type 2 Diabetes), Ecovac-4 (Vaccine for protection against the multiple strains of infectious agents) and Efecient (for iron deficiency).

The Company also launched ThankGod Relief Capsules, ThankGod Anytime Cream (a complete natural product for treatment of Haemorrhoids/ Piles), ThankGod Pain & Itch Relief Cream (for treatment of pain and itch), ThankGod Isabgol Husk (for treatment of constipation), Well-Beeing Capsules (for treatment of menstrual pain), Awayke MD tablets (for treatment of allergy) and Toff MD tablets (for treatment of common cold & cough) under umbrella brand name "Best on Health."

The company has entered into product licensing arrangements with renowned Research Institutes in India. It has an agreement with BCIL for manufacture & marketing of Anti-Anthrax Vaccine developed by JNU. Phase-I & II clinical trials of this vaccine have been initiated and the company foresees huge opportunities in India as well as global markets in view of the increased global risks of bio-terrorism especially in US and European countries.

Panacea Biotec has also entered into arrangements with NII for licensing of technology and processes for production of tissue culture-derived formalin inactivated Japanese Encephalitis Candidate Vaccine.